GPRC5D-Targeted CAR T Cells for Myeloma
Last Updated: Tuesday, December 27, 2022
Although disease relapse is common for patients with advanced myeloma who have received B-cell maturation antigen (BCMA)-targeted CAR T-cell therapies, the authors of this study confirmed that G protein-coupled receptor, class C, group 5, member D (CPRC5D) in an active immunotherapeutic target in multiple myeloma based on therapeutic response seen in 71% of the 17 patients included.
Advertisement
News & Literature Highlights
